ethyl 2-(1-(4-bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate | 185737-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 2-(1-(4-bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate
• 英文别名: ethyl 2-[1-[(4-bromophenyl)methyl]-5-methoxy-2-methylindol-3-yl]acetate
• CAS: 185737-95-5
• 化学式: C₂₁H₂₂BrNO₃
• 分子量: 416.315
• InChiKey: FHNLMKMJUSRPEO-UHFFFAOYSA-N

物化性质

• 沸点：
  549.2±50.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  40.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(1-(4-bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate 在 sodium hydroxide 作用下， 生成 p-Bromobenzyl-indomethacin
  参考文献：
  名称：

  Thiazole analogues of the NSAID indomethacin as selective COX-2 Inhibitors

  摘要：

  The carboxyl group of the NSAID indomethacin was replaced with a variety of substituted thiazoles to obtain a series of potent, selective inhibitors of COX-2. Additional substitutions were made at the 1-position and 5-position of the indole of indomethacin. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00212-8
• 作为产物：
  描述：

  乙酰丙酸乙酯 在 sodium acetate 、 sodium hydride 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 ethyl 2-(1-(4-bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate
  参考文献：
  名称：

  Thiazole analogues of the NSAID indomethacin as selective COX-2 Inhibitors

  摘要：

  The carboxyl group of the NSAID indomethacin was replaced with a variety of substituted thiazoles to obtain a series of potent, selective inhibitors of COX-2. Additional substitutions were made at the 1-position and 5-position of the indole of indomethacin. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00212-8

文献信息

• N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase
  申请人：Merck Frosst Canada, Inc.

  公开号：US05639780A1

  公开（公告）日：1997-06-17

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  本发明涵盖了具有式I的新型化合物，其在治疗环氧合酶-2介导的疾病中非常有用。 ##STR1## 本发明还涵盖了某些药物组合物，用于治疗环氧合酶-2介导的疾病，包括式I的化合物。
• Synthesis and biological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2
  作者：Y. Leblanc、W.C. Black、C.C. Chan、S. Charleson、D. Delorme、D. Denis、J.Y. Gauthier、E.L. Grimm、R. Gordon、D. Guay、P. Hamel、S. Kargman、C.K. Lau、J. Mancini、M. Ouellet、D. Percival、P. Roy、K. Skorey、P. Tagari、P. Vickers、E. Wong、L. Xu、P. Prasit

  DOI：10.1016/0960-894x(96)00101-1

  日期：1996.3

  Both enantiomers of L-761,000 were prepared and evaluated for their cyclooxygenase activities.
• US5639780A
  申请人：——

  公开号：US5639780A

  公开（公告）日：1997-06-17
• [EN] N-BENZYLINDOL-3-YL BUTANOIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS<br/>[FR] DERIVES D'ACIDE N-BENZYLINDOL-3-YLBUTANOIQUE EN TANT QU'INHIBITEURS DE LA CYCLOOXYGENASE-2
  申请人：MERCK FROSST CANADA INC.

  公开号：WO1996037467A1

  公开（公告）日：1996-11-28

  (EN) The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).(FR) Nouveau composé de formule (I) utile dans le traitement de maladies induites par la cyclooxygénase-2. La présente invention concerne en outre certaines compositions pharmaceutiques pour le traitement des maladies induites par la cyclooxygénase-2, qui contiennent des composés de la formule (I).
• Thiazole analogues of the NSAID indomethacin as selective COX-2 Inhibitors
  作者：Keith W. Woods、Richard W. McCroskey、Michael R. Michaelides、Carol K. Wada、Keren I. Hulkower、Randy L. Bell

  DOI：10.1016/s0960-894x(01)00212-8

  日期：2001.5

  The carboxyl group of the NSAID indomethacin was replaced with a variety of substituted thiazoles to obtain a series of potent, selective inhibitors of COX-2. Additional substitutions were made at the 1-position and 5-position of the indole of indomethacin. (C) 2001 Elsevier Science Ltd. All rights reserved.